IN SRL

Their core work

IN SRL is an Italian bioengineering SME that provides biofabrication, bioprocessing, and advanced materials capabilities to European research consortia. Their core work spans from designing bioreactor systems and microfluidic devices to engineering synthetic biological pathways for industrial applications. They contribute specialized bioprocess engineering to projects ranging from drug delivery systems and cancer tissue models to synthetic fuel production and crop improvement. Based in Udine, they operate as a versatile biotechnology service and development partner across life sciences, energy, and agriculture sectors.

What they specialise in

How they've shifted over time

IN SRL's early H2020 portfolio (2016-2017) focused on materials science and biomedical applications — ceramic composites for extreme environments, nanoparticle drug delivery for cardiovascular disease, and foundational work in synthetic photorespiration. From 2018 onward, the organization shifted decisively toward synthetic biology and bioprocess engineering, taking on projects in metabolic pathway design (eForFuel, SinFonia), 3D biofabrication for cancer research (B2B), and advanced crop engineering (GAIN4CROPS). This trajectory shows a clear consolidation around synthetic biology as their defining competence, applied across energy, health, and agriculture.

IN SRL is consolidating around synthetic biology and metabolic engineering as platform capabilities, applying them to industrial biotechnology challenges in energy and agriculture — expect future work in bio-based manufacturing and sustainable chemistry.

How they like to work

IN SRL operates primarily as a specialist partner (6 of 7 projects as participant), contributing targeted bioengineering capabilities to larger consortia. With 62 unique partners across 18 countries, they maintain a broad and diverse network rather than relying on repeat collaborations, suggesting they are sought after for specific technical contributions. Their one coordination role (eForFuel) shows ambition to lead when the topic aligns closely with their synthetic biology strengths.

Extensive European network spanning 62 unique partners across 18 countries, built through participation in mid-to-large RIA consortia. Their reach is genuinely pan-European with no obvious geographic concentration, reflecting their role as a sought-after specialist rather than a regionally embedded partner.

What sets them apart

IN SRL occupies an unusual niche as a bioengineering SME that bridges synthetic biology, biofabrication, and bioprocess engineering — disciplines that larger organizations often keep siloed. Their ability to contribute meaningfully to projects as diverse as cancer tissue modeling, synthetic fuel production, and crop yield improvement demonstrates rare cross-domain versatility rooted in a consistent bioprocess engineering core. For consortium builders, they offer the agility of an SME with the breadth of a research institute, particularly valuable when a project needs someone who can design, build, and operate biological production systems.

Highlights from their portfolio

• eForFuel
  Their only coordinated project — an ambitious effort to convert renewable electricity into hydrocarbon fuels via engineered microbial metabolism, signaling their leadership ambitions in industrial synthetic biology.
• SinFonia
  Largest single EC contribution (EUR 577,682) and a deep synthetic biology project engineering Pseudomonas putida for biofluorination — an industrially valuable and technically demanding application.
• GAIN4CROPS
  Their most recent project (running to 2026), applying synthetic photorespiration pathways to increase crop yields — positions them at the intersection of synthetic biology and sustainable agriculture.